Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 78% confidence The document is a “持续督导跟踪报告” prepared by the sponsor (方正证券) for an already listed company on the Shanghai Sci-Tech Innovation board, detailing the sponsor’s continuous oversight, risk items, financial data changes, and compliance with listing and regulatory rules. It is not the company’s annual or interim report, earnings release, or investor presentation, nor does it announce a dividend, share issue, or management change. It is a statutory follow-up report filed under stock exchange rules and securities issuance regulations, making it a general regulatory filing. Therefore, the correct classification is Regulatory Filings (RNS).
2026-05-19 Chinese
上海市锦天城律师事务所关于上海赛伦生物技术股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and voting results of a 2025 annual shareholders’ meeting. It primarily serves as a formal legal attestation/certification rather than the actual annual report or voting results announcement itself. Under the “Certification Rule,” such lawyer‐issued opinion letters are classified as general regulatory filings. Hence, it falls under Regulatory Filings (RNS).
2026-05-15 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司首次公开发行股票并在科创板上市持续督导保荐总结报告书
Regulatory Filings Classification · 73% confidence The document is a continuous supervision sponsorship summary report (‘持续督导保荐总结报告书’) provided by the underwriting sponsor on the issuer’s IPO and subsequent ongoing oversight. It is a substantive regulatory compliance report, not an annual or interim financial report, earnings release, capital transaction, governance code, ESG report, or other defined category. It does not announce the publication of another report but is the full report itself. There is no specific category for a sponsor’s oversight summary, so it falls into the catch-all “Regulatory Filings” category.
2026-05-12 Chinese
赛伦生物：自愿披露关于抗蜂毒血清获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shanghai Sairen Biotechnology Co., Ltd. regarding the receipt of a clinical trial approval notice for an anti-bee venom serum from the National Medical Products Administration. It details the drug's characteristics, clinical trial approval, and associated risks. The document is relatively short (1492 characters) and serves as a regulatory announcement about a clinical trial approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure about regulatory approval and clinical trial status.
2026-05-07 Chinese
赛伦生物：2025年年度股东会会议资料
AGM Information Classification · 100% confidence The document is titled as "2025年年度股东会会议资料" which translates to "2025 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items for the 2025 AGM, including reports such as the 2025 Board of Directors Work Report, 2025 Financial Final Accounts Report, profit distribution plans, remuneration proposals, and audit firm reappointment. The document includes meeting procedures, voting methods, and detailed proposals to be discussed and voted on at the AGM. It also includes the full text of the Board of Directors report and the financial report as attachments to the meeting materials. The document is lengthy (15,000 characters) and is clearly the presentation and materials shared during the AGM, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R).
2026-05-06 Chinese
赛伦生物：2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025年度募集资金存放、管理与实际使用情况的专项报告" which translates to "2025 Annual Report on the Storage, Management, and Actual Use of Raised Funds." It details the amount of funds raised, their management, usage, cash management activities, and compliance with regulatory requirements. It includes detailed financial tables about the raised funds, their usage, and cash management products. The document also references regulatory rules related to raised funds and includes auditor and sponsor opinions on the fund usage. This is a specialized report focused on the use and management of capital raised by the company, not a general annual report or earnings release. It is not a mere announcement or certification but contains substantive financial and management information about capital usage. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-04-24 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.